Effect of Pentoxifylline on GFR Decline in CKD: A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial

American Journal of Kidney Diseases

Volumn 53, Issue 4, 2009, Pages 606-616

  Perkins, Robert M ^a   Aboudara, Matthew C ^b   Uy, Alice L ^a   Olson, Stephen W ^b   Cushner, Howard M ^a   Yuan, Christina M ^b  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; estimated glomerular filtration rate; hypertension; pentoxifylline; proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RAMIPRIL; VALSARTAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; PILOT STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREMOR;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TREATMENT OUTCOME;

EID: 62749098612     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.026     Document Type: Article

References (30)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
2. John R., Webb M., Young A., and Stevens P.E. Unreferred chronic kidney disease: A longitudinal study. Am J Kidney Dis 43 (2004) 823-835
3. McClellan W., and Flaanders W. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14 suppl 2 (2003) S65-S70
4. Lewis E., Hunsicker L., Bain R., Rohde R., and Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
5. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
6. Brenner B.M., Cooper M.E., De Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
7. Maschio G., Alberti D., Janin G., et al., Angiotensin Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin converting enzyme benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 (1996) 939-945
8. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
9. Chen Y., Wu K., Tsai T., and Hsieh B. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-β-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 31 (1999) 773-783
10. Rao K., Currie M., McCachren S., and Cohen H. Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol 135 (1991) 314-325
11. Strutz F., Heeg M., Kochsiek T., Siemers G., Zeisberg M., and Muller G. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 15 (2000) 1535-1546
12. Hecht M., Muller M., Lohmann-Matthes M., and Emmendorffer A. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 57 (1995) 242-249
13. Segal R., Dayan M., Zinger H., and Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF-alpha monoclonal antibody and by pentoxifylline. Lupus 10 (2001) 23-30
14. Lin S., Chen Y., Chien C., Chiaang W., Tsai C., and Tsai T. Pentoxifylline attenuated renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13 (2002) 2916-2929
15. Navarro J., Mora C., Rivero A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33 (1999) 458-463
16. Solerte S., Fioravanti M., Bozzetti A., et al. Pentoxifylline, albumin excretion rate, and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetol Lat 23 (1986) 171-177
17. Rodriguez-Moran M., Gonzalez-Gonzalez G., Bermudez-Barba M., et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin Nephrol 66 (2006) 3-10
18. Aminorroaya A., Janghorbani M., Rezvanian H., Aminian T., Gharavi M., and Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 99 (2005) c73-c77
19. Rodriguez-Moran M., and Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients-A randomized, equivalent trial. Clin Nephrol 64 (2005) 91-97
20. Chen Y., Lin S., Chiang W., Wu K., and Tsai T. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 69 (2006) 1410-1415
21. Navarro J., Mora C., Muros M., Macia M., and Garcia J. Effects of pentoxifylline administration on urinary N-acetyl-B-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomized study. Am J Kidney Dis 42 (2003) 264-270
22. Levey A., Greene T., Kusek T., and Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 155A (abstr)
23. Maroni B.J., Steinman T.I., and Mitch W.E. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27 (1985) 58-65
24. Peterson J.C., Adler S., Burkhart J., et al. Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 123 (1995) 754-762
25. Navarro J., Mora C., Muros M., and Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short term, randomized, controlled trial. J Am Soc Nephrol 16 (2005) 2119-2126
26. Harmankaya O., Seber S., and Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25 (2003) 465-470
27. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., and Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis 52 (2008) 454-463
28. Diskin C., Stokes J., Dansby L., Radcliff L., and Carter T. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both and angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?. J Nephrol 20 (2007) 410-416
29. Lin S.L., Chen Y.M., Chaing W.C., Wu K.W., and Tsai T.J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: A 12-month randomized trial. Am J Kidney Dis 52 (2008) 464-474
30. Cho M.E., Smith D.C., Branton M.H., Penzak S.R., and Kopp J.B. Pirfenidone slows renal clearance function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2 (2007) 906-913